{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:40:44Z","timestamp":1794555644850,"version":"4.9.1"},"reference-count":31,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"unspecified","delay-in-days":146,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hellenic Society of Rheumatology & Professionals Union of Rheumatologists of Greece","award":["1494\/23.12.25"],"award-info":[{"award-number":["1494\/23.12.25"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,4,27]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) are associated with improved outcomes in SLE; however, their value in lupus nephritis (LN) remains unexplored. We sought to evaluate their prognostic value on organ damage accrual, renal flares and chronic kidney disease in patients with LN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multicentre retrospective cohort study of patients with biopsy-proven LN who achieved renal response. Enrolment date was the time of first renal response. Longitudinal data were analysed using Cox proportional hazards models. Modified LLDAS (mLLDAS) and DORIS (mDORIS) attainment and sustained durations were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>155 patients with 1703 visits were included. During a median follow-up of 3.5 years (IQR 4.5), 127 patients (81.9%) achieved mLLDAS and 92 (59.4%) achieved mDORIS. Both states demonstrated robust protective effects across all outcomes. For organ damage, mLLDAS attainment was associated with 85% risk reduction (adjusted HR (aHR 0.15, 95%\u2009CI 0.07 to 0.32), while mDORIS conferred a 79% reduction (aHR 0.21, 95%\u2009CI 0.08 to 0.55). Periods under mLLDAS were also associated with a 73% reduction in renal flare risk (aHR 0.27, 95%\u2009CI 0.14 to 0.51), with similar effects for mDORIS. Sustained achievement resulted in progressively greater protection, with the strongest effects seen for \u226524 consecutive months. Early attainment protected against damage accrual (aHR 0.31, 95%\u2009CI 0.16 to 0.61)\u2009and renal flares (aHR 0.51, 95%\u2009CI 0.29 to 1.00).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Following renal response, achievement of mLLDAS and mDORIS is strongly associated with improved outcomes in LN patients. Earlier attainment and longer duration in these states confer progressively greater protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-002021","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:30:15Z","timestamp":1779892215000},"page":"e002021","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0143-6404","authenticated-orcid":false,"given":"Konstantinos","family":"Drougkas","sequence":"first","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Katechis","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Kostopoulou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \"G. Gennimatas\u201d General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Tsalapaki","sequence":"additional","affiliation":[{"name":"Clinical Immunology- Rheumatology Unit, 2nd Department of Medicine and Laboratory, General Hospital of Athens Hippokration, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-5847","authenticated-orcid":false,"given":"Sofia","family":"Flouda","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-0693","authenticated-orcid":false,"given":"Maria","family":"Pappa","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Bakula","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Croatian Referral Centre for SLE and Related Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Padjen","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Rheumatology, Croatian Referral Centre for SLE and Related Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Nikoloudaki","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical Immunology and Allergy Department, University Hospital of Heraklion, University of Crete, School of Medicine, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinelopi","family":"Konstantopoulou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \"G. Gennimatas\u201d General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Moustakas","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \"G. Gennimatas\u201d General Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[{"name":"Clinical Immunology- Rheumatology Unit, 2nd Department of Medicine and Laboratory, General Hospital of Athens Hippokration, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5299-1406","authenticated-orcid":false,"given":"George","family":"Bertsias","sequence":"additional","affiliation":[{"name":"Rheumatology, Clinical Immunology and Allergy Department, University Hospital of Heraklion, University of Crete, School of Medicine, Heraklion, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi V","family":"Voulgari","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Ioannina, Faculty of Medicine, Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-4671","authenticated-orcid":false,"given":"Dimitrios T","family":"Boumpas","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2696-031X","authenticated-orcid":false,"given":"Antonis","family":"Fanouriakis","sequence":"additional","affiliation":[{"name":"Rheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2026102912501461000_13.1.e002021.1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026102912501461000_13.1.e002021.2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1093\/ndt\/gfac304","article-title":"The influence of repeated flares in response to therapy and prognosis in lupus nephritis","volume":"38","author":"Perez-Arias","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026102912501461000_13.1.e002021.3","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.528"},{"key":"2026102912501461000_13.1.e002021.4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"2026102912501461000_13.1.e002021.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2026102912501461000_13.1.e002021.6","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026102912501461000_13.1.e002021.7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.31138\/mjr.290424.eci","article-title":"Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus","volume":"35","author":"Nikolopoulos","year":"2024","journal-title":"Mediterr J Rheumatol"},{"key":"2026102912501461000_13.1.e002021.8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/acr.25611","article-title":"Reduction in Renal Relapse and Preservation of Long\u2010Term Kidney Function After Lupus Low Disease Activity in Patients With Lupus Nephritis","volume":"78","author":"Cheung","year":"2026","journal-title":"Arthritis Care & Research"},{"key":"2026102912501461000_13.1.e002021.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.34473"},{"key":"2026102912501461000_13.1.e002021.10","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930"},{"key":"2026102912501461000_13.1.e002021.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000108969.21691.5D"},{"key":"2026102912501461000_13.1.e002021.12","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026102912501461000_13.1.e002021.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2026102912501461000_13.1.e002021.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201940"},{"key":"2026102912501461000_13.1.e002021.15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-024-03275-z"},{"key":"2026102912501461000_13.1.e002021.16","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2023.10.018"},{"key":"2026102912501461000_13.1.e002021.17","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard-2022-222487","article-title":"Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026102912501461000_13.1.e002021.18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11926-023-01109-6","article-title":"Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention","volume":"25","author":"Banos","year":"2023","journal-title":"Curr Rheumatol Rep"},{"key":"2026102912501461000_13.1.e002021.19","doi-asserted-by":"crossref","unstructured":"Carlucci PM , Preisinger K , Deonaraine KK , et al . Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA\/SLE Lupus Nephritis Network. Rheumatology (Sunnyvale) 2024. doi:10.1093\/rheumatology\/keae189","DOI":"10.1093\/rheumatology\/keae189"},{"key":"2026102912501461000_13.1.e002021.20","doi-asserted-by":"crossref","first-page":"1546306","DOI":"10.3389\/fimmu.2025.1546306","article-title":"Transitioning from Lupus Low Disease Activity State to remission in systemic lupus erythematosus: real-world evidence","volume":"16","author":"Gao","year":"2025","journal-title":"Front Immunol"},{"key":"2026102912501461000_13.1.e002021.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1163-2","article-title":"Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort","volume":"18","author":"Golder","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026102912501461000_13.1.e002021.22","first-page":"1648","article-title":"Predictors of predominant Lupus Low Disease Activity State (LLDAS-50)","volume":"28","author":"Babaoglu","year":"2019","journal-title":"Lupus (Los Angel)"},{"key":"2026102912501461000_13.1.e002021.23","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180433"},{"key":"2026102912501461000_13.1.e002021.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1232244","article-title":"Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"2026102912501461000_13.1.e002021.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05940-z"},{"key":"2026102912501461000_13.1.e002021.26","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","article-title":"Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study","volume":"6","author":"Golder","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026102912501461000_13.1.e002021.27","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001206","article-title":"Patients achieving low lupus disease activity state, systemic lupus erythematosus disease control or remission showed lower rates of organ damage during longitudinal follow-up: analysis of the Hopkins Lupus Cohort","volume":"11","author":"Hunnicutt","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2026102912501461000_13.1.e002021.28","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70007","article-title":"Frequency and Determinants of Flare and Persistently Active Disease in a Large Multinational Prospective Lupus Cohort","volume":"7","author":"Hao","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026102912501461000_13.1.e002021.29","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","article-title":"Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study","volume":"5","author":"Cho","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026102912501461000_13.1.e002021.30","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/rheumatology\/keae120","article-title":"Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up","volume":"64","author":"Parodis","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026102912501461000_13.1.e002021.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224919"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:50:25Z","timestamp":1793303425000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2026-002021"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002021","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}